Grade 3/4 adverse events (AEs) of second generation tyrosine kinase inhibitors (TKIs) for imatinib resistant/intolerant patients in accelerated phase CML (AP-CML) No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results